U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Lincare, Inc. - Close Out Letter 3/5/18
  1. Warning Letters

CLOSEOUT LETTER

Lincare, Inc.


Recipient:
Lincare, Inc.


United States

Issuing Office:

United States


 

  

Black HHS-Blue FDA Logo

 

Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204 

 
 

March 5, 2018

VIA UPS EXPRESS

Gregory McCarthy, CEO
Lincare Holdings, Inc.
19387 US 19 N
Clearwater, Florida 33764-3102

Dear Mr. McCarthy:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter #2016-DAL-WL-19 dated April 25, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have any further questions, you may contact me at (214) 253-5288.

Sincerely,
/S/

LCDR John W. Diehl, M.S.
Director, Compliance Branch
Office of Pharmaceutical Quality Operations, Division II 

 

Cc: Chelsey Chandler, Center Manager
Lincare, Inc. dba United Medical Home Infusion
1527 S. Bowman Road, Suite D
Little Rock, Arkansas 72211-4200